Australia
· Delayed Price · Currency is AUD Invion Company Description
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia.
The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers.
It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.
Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
| Country | Australia |
| Founded | 2000 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Thian Chew |
Contact Details
Address: 100 Albert Road Melbourne, 3205 Australia | |
| Phone | 61 3 9692 7222 |
| Website | inviongroup.com |
Stock Details
| Ticker Symbol | IVX |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000IVX4 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thian Chew | Executive Chairman and Chief Executive Officer |
| Melanie Jaye Leydin B.Bus, C.A., CA | Chief Financial Officer, Company Secretary and Non-Executive Director |
| Dr. Dean Naylor | Head of Intellectual Property Development |